Vitamin A+Citric
    Publish time 2026-10-16 13:56    

Quadrivalent Antibody
This product boasts unique production  
processes, easier strain updates, wider coverage, higher oral absorption rate,  better stability, enhanced safety, and more significant clinical efficacy.

Vitamin A+Citric

I. Product Overview This product is a set of functional immunoglobulins expressed via genetic  recombination technology. These immunoglobulins cover various prevalent  viral strains in China, including all types of avian adenovirus, Newcastle  disease virus, influenza virus subtype H9, as well as classical and variant  strains of infectious bursal disease virus. Compared with the yolk antibodies  commonly used in the market, this product boasts unique production  processes, easier strain updates, wider coverage, higher oral absorption rate,  better stability, enhanced safety, and more significant clinical efficacy. II. Main Ingredients Genetically recombinant immunoglobulins, taurine, etc. III. Product Features (I) Quadrivalent Targeting for Precise Protection Exclusively integrating four core immunoglobulins, it adopts the innovative  quadrivalent immune protein complex technology to simultaneously prevent  and control four major threats: avian adenovirus, Newcastle disease, influenza  H9, and variant strains of infectious bursal disease. It targets and eliminates  viruses, reduces the risk of mixed infections, and truly achieves "one dose for  multiple protections". Adenovirus genetically recombinant protein – Covers all currently prevalent  pathogenic strains (Group I, Types C, D, E), and effectively prevents and  controls pericardial effusion, inclusion body hepatitis, gizzard erosion, and  ulceration. Newcastle disease genetically recombinant protein – Covers Newcastle  disease virus Genotype II and Genotype VII, and effectively prevents and  controls Newcastle disease in chickens, as well as paramyxovirus in ducks  and geese. Influenza H9 genetically recombinant protein – Effectively blocks respiratory  issues, mixed infections, and decreased immunity caused by widespread  influenza H9 infection. Infectious bursal disease genetically recombinant protein – Overcomes variant  strains and addresses immune suppression, low feed intake, and high  mortality rates caused by latent infectious bursal disease virus infection.